{
  "ticker": "BMY",
  "content": "**Report Generated:** January 14, 2026  \n**Next Refresh:** April 15, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Bristol-Myers Squibb Company (BMY) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nBristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.\n\nIn 2024, 71% of the company's revenues came from the United States. The company operates through two main portfolios: Growth Products and Legacy Products. The company's primary products are Apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues).\n\n## 2. Current Market Data\n\nAs of today, Bristol-Myers Squibb(BMY) shares are valued at $56.06. The company's market cap stands at 114.2B, with a P/E ratio of 18.86 and a dividend yield of 4.4%. In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52. Over the past 4 weeks, Bristol-Myers Squibb lost 2.72%, and in the last 12 months, it decreased 2.55%.\n\n## 3. Existing Products/Services\n\n### Growth Portfolio Products:\n• Eliquis (apixaban): Top seller, though facing IRA pricing pressure from 2026. Opdivo (nivolumab): Leading immuno-oncology therapy, with a subcutaneous formulation launched in January 2025.\n• Breyanzi (lisocabtagene maraleucel): CAR T cell therapy, FDA-approved for five cancer types as of December 4, 2025.\n• Camzyos (mavacamten): First cardiac myosin inhibitor for hypertrophic cardiomyopathy.\n• Opdualag (nivolumab + relatlimab): Immuno-oncology combination.\n• Cobenfy (KarXT): Novel schizophrenia treatment, launched October 2024.\n• Reblozyl (luspatercept): Strong growth for anemia treatment.\n\n### Legacy Portfolio Products:\nLegacy Products: Include Revlimid, Pomalyst/Imnovid, Orencia, Sprycel, Zeposia, Abecma, Krazati, Augtyro, and Abraxane, which are facing increasing generic competition.\n\n### Support Services:\nServices: While primarily a drug developer, BMS offers specialized support such as Cell Therapy 360 (a digital platform for Breyanzi) and the Eliquis 360 Support program, providing direct-to-patient options to improve access and affordability.\n\n## 4. Planned Products/Services/Projects\n\n### Pipeline Highlights:\n• Cardiovascular: Milvexian (oral Factor XIa inhibitor for stroke prevention) with Phase 3 results expected in 2026.\n• Neuroscience: Cobenfy (KarXT) expansion for adjunctive schizophrenia and Alzheimer's disease (data expected 2025/2026).\n• Highly anticipated Phase 3 results for milvexian in atrial fibrillation and secondary stroke prevention, admilparant in idiopathic pulmonary fibrosis, and the two CELMoD drugs—iberdomide and mezigdomide—in previously treated myeloma.\n\n### Upcoming Drug Registrations (2026-2028):\nBristol Myers has 13 drugs that expect to have NME registrational data between 2026 to 2028. LCM pivotal data is expected for 14 indications during the same time period.\n\n### Radiopharma Portfolio:\nRadiopharma Commercialization: Expected to begin in 2026-2028 from the RayzeBio acquisition.\n\n## 5. Growth Strategy\n\nBristol-Myers Squibb's Q3 2024 earnings call signals a company in transition, with a clear strategy to pivot towards sustainable, long-term growth driven by a revitalized pipeline and key drivers: the young, growing portfolio (Cobenfy, Breyanzi, Reblozyl, Camzyos, Opdualag, Opdualag subcu), pipeline progress (Milvexian, LPA1, Iberdomide, Mezigdomide), and financial discipline.\n\nBristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. \"business development remains a top priority\" for the company's capital allocation strategy heading into 2026.\n\n### Cost Management:\nThe pharmaceutical giant still plans to cut $1.5 billion in costs by the end of 2025 and funnel that money into drug development. Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth.\n\n### R&D Investment:\nInnovation Pipeline and R&D Efforts: BMS invested $11.16 billion in R&D in 2024 and plans to invest $40 billion in the U.S.\n\n## 6. Current and Potential Major Clients\n\nIt sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company serves both domestic and international markets, with strong presence in oncology, immunology, and cardiovascular therapeutic areas through its extensive distribution network.\n\n### Geographic Distribution:\nRevenues International 31% indicating that approximately 69% of revenues come from domestic (US) markets.\n\n## 7. Financial Data & Performance\n\n### Recent Financial Performance:\nBristol Myers posted net income of $72 million, or 4 cents per share, for the fourth quarter. The pharmaceutical giant's revenue rose 8% from the same period a year ago to $12.34 billion.\n\nEliquis booked $3.2 billion in sales for the quarter, up 11% from the year-ago period. That is above the $3.03 billion that analysts were expecting, according to estimates compiled by StreetAccount.\n\n### 2025 Guidance:\nWe estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid , Pomalyst , Sprycel and Abraxane , which we expect to result in a revenue decline of approximately 18-20% of the Legacy Portfolio.\n\nBristol-Myers Squibb has raised its full-year 2025 financial guidance, reflecting confidence in its business momentum and strategic execution. Full-Year Revenue Guidance: Increased to $45.8 billion to $46.8 billion, up from previous estimates.\n\n## 8. Market Shares\n\nBristol-Myers Squibb holds significant positions in global pharmaceutical markets:\n\nBristol-Myers Squibb - US$45bn. In ninth place in 2025 is global biopharma, Bristol-Myers Squibb (BMS). With a legacy in healthcare innovation dating back to the early 1800s, the company has made significant medical advances in oncology, hematology, immunology and cardiovascular disease.\n\nMerck, Johnson & Johnson, Bristol Myers Squibb each of them has 5% market share. Pfizer has 7% of the market share. This positioning places BMS among the top pharmaceutical companies globally with significant market presence across therapeutic areas.\n\n## 9. Comparison to Competitors\n\nPfizer - US$58.5bn · Merck & Co - US$53.6bn · Roche - US$49.9bn · Novartis - US$45.4bn · Bristol-Myers Squibb - US$45bn places BMS as the 9th largest pharmaceutical company globally.\n\n### Pipeline Competitiveness:\nAstraZeneca and Bristol-Myers Squibb are a close second; their only potential weakness is a late-stage tilt. Roche, AstraZeneca, and Bristol-Myers Squibb sit in a comfortable position at the top of the rankings. in terms of pharmaceutical R&D pipeline strength.\n\nBristol-Myers Squibb's top 19 competitors are AbbVie, Amgen, Pfizer, Merck, Sanofi, Novartis, Roche, Gilead Sciences, GSK, AstraZeneca, Lilly, Genentech, Abbott, Johnson & Johnson, Teva, Bayer , Boehringer Ingelheim, Biogen and Cipla.\n\n## 10. Partnerships, Mergers and Acquisitions\n\n### Recent Major Acquisitions:\n• In January 2024, BMS acquired Mirati Therapeutics, an American biotechnology company that develops targeted therapies for the treatment of cancer, for $4.8 billion, and an additional $1 billion in milestone payment.\n• In March 2024, BMS acquired Karuna Therapeutics for $14 billion. The acquisition included Karuna's lead asset, KarXT, an investigational muscarinic antipsychotic combination of Xanomeline and Trospium for the treatment of schizophrenia in adults.\n• In February 2024, the company acquired RayzeBio for approximately $4.1 billion.\n\n### Strategic Partnerships:\n• $3.5 Billion Investment with Up to $7.6 Billion in Milestones BMS will pay $1.5 billion upfront and $2 billion in non-contingent payments through 2028, with potential milestone payments reaching up to $7.6 billion. in partnership with BioNTech for BNT327.\n• In return, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs.\n• In July 2025, the company announced a joint venture with Bain Capital to launch an independent immunology-focused firm, backed by $300 million in financing.\n\n## 11. Recent Developments\n\n### Key Drug Approvals:\n• In September 2024, the Food and Drug Administration approved Cobenfy, the first novel type of treatment for schizophrenia in 70 years.\n• William Blair estimates Cobenfy could achieve peak sales of $2 billion in 2030 in schizophrenia alone.\n\n### Pipeline Updates:\n• In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsychotic at Week 6, which did not reach the threshold for statistical significance for the primary endpoint (P = 0.11).\n• After a blinded review and consultation with the FDA, the company decided to exclude data from those sites and enroll additional patients to restore study integrity. Additional readouts from the ADEPT program (ADEPT‑1, -2 and -4) are expected by end‑2026.\n\n### Analyst Updates:\nBristol Myers price target raised to $60 from $54 at Leerink and Cantor Fitzgerald (Nov 24; highlighted Dec 3 coverage): Reaffirmed a Neutral rating and $45 target, calling recent FXIa data \"a needed win\" for BMY's milvexian program but noting that sentiment will ultimately hinge on future ADEPT‑2 and milvexian Afib trial readouts.\n\n## 12. AI Investment Rating & Fair Value Assessment\n\nBased on the comprehensive analysis, Bristol-Myers Squibb presents a compelling investment opportunity for growth-oriented portfolios with moderate risk tolerance:\n\n**Strengths:**\n- Strong pipeline with 10+ potential drug launches by 2030\n- Recent successful acquisitions adding significant value (Karuna's Cobenfy, RayzeBio's radiopharma platform)\n- Robust R&D investment ($11.16B in 2024)\n- Disciplined cost management with $2B cost reduction by 2027\n- Strong market position across multiple therapeutic areas\n- Attractive dividend yield of 4.4%\n\n**Challenges:**\n- Patent cliff pressures from legacy products (Eliquis, Opdivo facing generics by 2028)\n- Mixed pipeline trial results (Cobenfy adjunctive therapy missed primary endpoint)\n- Revenue decline expected in 2025 due to generic competition\n\n**Growth Catalysts:**\n- Milvexian Phase 3 data (2026) for cardiovascular indications\n- Cobenfy expansion opportunities (Alzheimer's psychosis by 2026)\n- Radiopharma commercialization (2026-2028)\n- Strategic partnerships with BioNTech and others\n\n**Valuation Considerations:**\nBristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x.\n\n**Investment Rating: 7.8/10**\n\nThis rating reflects the company's strong fundamentals, robust pipeline potential, and strategic positioning, tempered by near-term patent cliff challenges. The valuation discount provides attractive entry point for long-term investors.\n\n**Estimated Fair Value: $65-70 per share**\n\nThis target is based on the pipeline value inflection expected from 2026-2028 data readouts, successful navigation of patent cliff challenges, and the company's demonstrated ability to execute strategic acquisitions and partnerships. The current trading price of ~$56 suggests significant upside potential for investors with 2-3 year investment horizon.",
  "generated_date": "2026-01-14T08:31:06.528675",
  "next_refresh_date": "2026-04-15T08:31:06.528675",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.37149045,
  "tokens": {
    "input": 183,
    "output": 4823,
    "cache_creation": 65143,
    "cache_read": 181034
  },
  "tldr_summary": "Bristol-Myers Squibb is a global biopharmaceutical company developing transformative medicines for serious diseases, with a strong focus on oncology, hematology, and immunology. The company is strategically pivoting towards sustainable growth through a revitalized pipeline, key product launches like Cobenfy (schizophrenia treatment), and strategic acquisitions in emerging therapeutic areas, including a $14B Karuna Therapeutics purchase and radiopharma expansion. With significant R&D investments ($11.16B in 2024), the company aims to launch over 10 new medicines by 2030, while managing patent cliff challenges for legacy products like Eliquis and Opdivo. Market positioning remains strong, ranking 9th globally in pharmaceuticals with a diverse portfolio spanning cardiovascular, neuroscience, and cancer treatments. Upcoming catalysts include Phase 3 data for milvexian in cardiovascular indications and potential Cobenfy expansion.\n\nAI Investment Rating: 7.8/10, with a fair value estimate of $65-70, reflecting strong pipeline potential and current undervaluation, recommending a long-term investment approach."
}